Redeemable Convertible Preferred Shares and Capital Deficiency (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2026

Dec. 31, 2025

Redeemable Convertible Preferred Shares and Capital Deficiency [Abstract]

Schedule Of Redeemable Convertible Preferred Shares

The Company’s Redeemable Convertible Preferred Shares, par value NIS 0.01 each, confer to their holders the same rights as the Ordinary Shares and additional rights as set forth in the article of association.

		December 31, 2025								December 31, 2024								Carrying amount								Liquidation Preference
		Registered				Issued and Outstanding				Registered				Issued and Outstanding				December 31, 2025				December 31, 2024				December 31, 2025				December 31, 2024
Ordinary Shares			7,192,608				836,512				8,796,571				651,571
Preferred A Shares			416,389				324,202				416,389				324,202				3,802				3,802				4,980				4,743
Preferred A-1 Shares			190,984				190,984				190,984				190,984				1,700				1,700				2,200				2,095
Preferred A-2 Shares			430,806				223,489				430,806				223,489				3,593				3,593				4,118				3,922
Preferred A-3 Shares			165,250				165,250				165,250				165,250				2,685				2,685				2,436				2,320
Preferred B Shares			800,000				—				—				—				—				—				—				—
Preferred C Shares			733,452				165,633				—				—				2,431				—				2,600				—
Preferred C-1 Shares			70,511				67,368				—				—				1,057				—				846				—
Total																			15,268				11,780				17,180				13,080

Schedule of Stock-based Expense Recognized

The stock-based expense recognized in the financial statements for services received is related to Research and Development, Sales and Marketing and General and Administrative expenses as shown in the following table:

		Year ended December 31, 2025				Year ended December 31, 2024
		USD thousands				USD thousands
Stock-based compensation expense – Research and development			1,094				577
Stock-based compensation expense – sales and marketing			555				51
Stock-based compensation expense – general and administrative			1,375				923
			3,024				1,551

Schedule of Foreseeable Plans to Pay Dividends

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model that used the weighted average assumptions in the following table.


		2026 Grants
Dividend yield		$	-
Expected volatility			60.78 – 61.84	%
Risk-free interest			3.77 – 3.82	%
Expected term			5.64 – 6.13 years
Exercise price		$	0.16 – 9.37
Share price		$	11
Total fair value (USD Thousands)		$	626

The Company has historically not paid dividends and has no foreseeable plans to pay dividends.

		Granted in 2025		Granted in 2024
Dividend yield		0		0
Expected volatility⁽¹⁾		62.27% – 63.01%		59.33% – 61.60%
Risk-free interest (%)		4.65 – 4.76		4.69 – 4.70
Expected term⁽²⁾		5 – 7 years		5 – 7 years
Exercise price ($)		0.57 – 27.19		0.57 – 10.62
Total fair value at the grant date (USD thousands)		4,617		1,268
Weighted average fair value at the grant date		$27.47		$17.89

Assumptions regarding the price of the underlying shares:
Probability of an IPO		90%		40%
Expected time to IPO (years)		0.5		1
Probability of liquidation event		10%		60%
Expected time to liquidation (years)		3		3

(1)	The annual expected volatility was applied, based on the average historical volatility of comparable companies for a period equal to the expected period, as of the valuation date.

(2)

Expected term (years) — represents the period that the Company’s options granted are expected to be outstanding. There is not sufficient historical share exercise data to calculate the expected term of the share options. Therefore, the Company elected to utilize the simplified method to value option grants. Under this approach, the weighted-average expected life is presumed to be the average of the shortest vesting term and the contractual term of the option.

Schedule of Share Option Plan Activity

A summary of the Company’s share option plan activity is as follows:

		Year ended December 31, 2025
		Number of options				Weighted average exercise price (USD)				Aggregate Intrinsic Value (USD thousands)
Outstanding at beginning of year			324,353				1.59
Granted			192,800				8.61				5,438
Forfeited and expired			(35,148	)			6.31
Exercised			(175,049	)			0.02				3,931
Outstanding at end of year			306,956				6.35				9,351
Exercisable at end of year			174,699				5.41				5,486

		Year ended December 31, 2025				Year ended December 31, 2024
Weighted average remaining contractual term (years) of outstanding grants			8.17				8.38
Weighted average remaining contractual term (years) of exercisable grants			7.61				8.17
Aggregate Intrinsic Value, outstanding (USD thousands)			9,351				8,394
Aggregate Intrinsic Value, exercisable (USD thousands)			5,486				5,742